12/12
12:37 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
12/12
12:19 pm
trvi
Rating for TRVI
High
Report
Rating for TRVI
12/12
12:19 pm
trvi
Rating for TRVI
High
Report
Rating for TRVI
12/4
12:56 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/4
08:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
12/4
06:21 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
12/4
06:21 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/8
08:46 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
11/8
04:30 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/8
04:30 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
10/22
08:32 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/7
11:28 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
10/7
11:28 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
10/4
01:35 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
10/4
01:28 pm
trvi
Rating for TRVI
Low
Report
Rating for TRVI
10/4
01:28 pm
trvi
Rating for TRVI
Low
Report
Rating for TRVI